Is IN8BIO, INC. (INAB) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 29.9% / 30% | 66.2% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 29.9% / 33% | 66.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 24.0% / 33% | 53.1% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 29.9% / 33% | 66.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 24.0% / 33% | 53.1% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -92.5% | |
| Return on Assets (ROA) | -46.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$13M |
| Free Cash Flow | -$13M |
| Total Debt | $3M |
| Debt-to-Equity | 10.1 |
| Current Ratio | 8.8 |
| Total Assets | $32M |
Price & Trading
| Last Close | $1.47 |
| 50-Day MA | $1.88 |
| 200-Day MA | $2.03 |
| Avg Volume | 86K |
| Beta | 0.0 |
|
52-Week Range
$1.17
| |
About IN8BIO, INC. (INAB)
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is IN8BIO, INC. (INAB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), IN8BIO, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is IN8BIO, INC.'s debt ratio?
IN8BIO, INC.'s debt ratio is 29.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 24.0%.
What are IN8BIO, INC.'s key financial metrics?
IN8BIO, INC. has a market capitalization of $14M. Return on equity stands at -92.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.